API Quick Links: http://en.hichipharm.com/

+86-152-0110-8103 yanglm@beilupharma.com

EN

EN
jp
fr
de
es
ru
pt
ar

- English
- 日本語
- français
- Deutsch
- Español
- русский
- português
- العربية

Beilu Pharmaceutical Obtains GMP Certification from ANVISA

2024/11/01

Recently, Beijing Beilu Pharmaceutical Co., Ltd.'s contrast agent production linepassed the GMP (Good Manufacturing Practice) certification by Brazil's National Health Surveillance Agency (ANVISA).

Brazil is the largest country in South America. Beilu Pharmaceutical's successful passing of the Brazil's ANVISA GMP certification this time has created conditions for the company's contrast agent products to successfully enter the Brazilian market and has a very positive effect on the company further expanding the Brazilian market and other international markets.

In the first three quarters of 2024, Beilu Pharmaceutical's overseas market business progressed smoothly, with continuous growth in overseas revenue. While the pace of overseas registration for contrast agent products is accelerating, Hichi Pharmaceuticals' iodine APIs continue to expand in the overseas market, and gadolinium APIs produced by the Cangzhou subsidiary are also gradually achieving internationalization. At present, the company's products have been sold to 26 countries, with additional registrations ongoing in 30 other countries or regions. As the company successfully passes the ANVISA GMP certification, the competitiveness of its products in international markets will be further enhanced, and the pace of internationalization is expected to accelerate.

Related Products

Iohexol Injection

Iohexol Injection

Gadobenate Dimeglumine Injection

Gadobenate Dimeglumine Injection

Related News

Adverse Reaction and Treatment of Contrast Medium
December 3, 2020Adverse drug reactions refer to harmful reactions that have nothing to do with the purpose of medication or accidentally occur under normal usage and dosage of qualified drugs.view
Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 20 Industry Guidelines Consensus Teaching Materials
December 1, 2023The flagship product, Jiuwei Zhenxin Granules, a central nervous system medication developed by Beilu Pharmaceutical, has been included in the "Guidelines for the Diagnosis and Treatment of Ankyl...view
Beilu Pharma's Gadobutrol Injection Has Been Approved By NMPA
April 8, 2022Beijing Beilu Pharmaceutical Co., Ltd. (300016) announced today that Gadobutrol injection has obtained the "Drug Registration Certificate" issued by the NMPA（National Medial Production Administr...view
Uses of Ferric Ammonium Citrate
December 27, 2021Ferric ammonium citrate is classified as a nutritional supplement, and it belongs to iron supplements. It is often used in the production and processing of wheat flour, cookies or baby milk powder. It...view
Beilu Pharmaceutical Intends to Establish a Wholly-owned Subsidiary in Hong Kong
December 27, 2022In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...view
Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement
June 24, 2021Beilu Pharma participated in the fifth round of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use of the Joint Procurement Office.view

Call us on:
+86-152-0110-8103
Email Us:
yanglm@beilupharma.com
No.3 Shuiyuan West Road, Miyun District, Beijing, China

Sitemap | Privacy Policy
Copyright © Beijing Beilu Pharmaceutical Co., Ltd. All Rights Reserved.

+86-152-0110-8103